---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-030757"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-09-18T21:00:57+00:00"
generated_at: "2026-09-18T21:02:16.446358+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech receives Nasdaq delisting notice; bid price below $1 for 30 days

## Summary
- Nasdaq notified Moleculin on Sept 15, 2026 that common stock failed minimum bid price ($1) from July 31 to Sept 11, 2026.
- Company ineligible for 180-day cure period due to 1-for-25 reverse stock split effected Dec 1, 2025.
- Company will request a hearing before Nasdaq Hearings Panel; trading continues pending panel decision.
- No assurance of continued listing; risk of suspension or delisting if hearing fails.

## SEC filing metadata
- accession: 0001437749-26-030757
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-09-18T21:00:57+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926030757/0001437749-26-030757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926030757/mbrx20260914_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-030757
- JSON: https://secwatch.observer/filing/0001437749-26-030757.json
- Plain text: https://secwatch.observer/filing/0001437749-26-030757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.